Keynote Panel: Big pharma perspective in driving Asia biopharma innovation
With the highest amount of resources which can be invested into operation, big pharma companies are in the best position to lead the industry direction. When making a key decision, it is important to understand the impact in organisation and industry wide. How can big pharma avoid being "too-big-to-fail" and lead the industry to be more innovative?
Paul Song, Vice President, Business Development, Samsung Bioepis
Ms Melinda Richter, Head of JLABS, Johnson & Johnson
Atin Tomar, President, CPL Biologicals
Rajesh Krishna, Executive Director, Translational Pharmacology, MSD Singapore